Top 10 Small-Cap Biotechs with Upcoming Catalysts for 2025

Here are 10 small cap biotech stocks with notable upcoming catalysts in 2025—ranging from trial readouts and FDA decisions to pivotal data and corporate milestones:
________________________________________
🔬 Top 10 Small-Cap Biotechs with Upcoming Catalysts for 2025
1. Crinetics Pharmaceuticals (NASDAQ: CRNX)
• Catalyst: FDA PDUFA deadline for paltusotine (oral acromegaly treatment) expected by September 25, 2025.
• Focused on endocrine diseases and advancing pipeline beyond acromegaly (en.wikipedia.org).
Stock market information for Crinetics Pharmaceuticals Inc (CRNX)
• Crinetics Pharmaceuticals Inc is a equity in the USA market.
• The price is 32.33 USD currently with a change of -0.73 USD (-0.02%) from previous close.
• The latest open price was 33.1 USD and the intraday volume is 420639.
• The intraday high is 33.34 USD and the intraday low is 32.32 USD.
• The latest trade time is Wednesday, June 11, 23:45:00 +0300.
________________________________________
2. Viking Therapeutics
• Catalyst: Late-stage trial start for injectable weight-loss drug (GLP 1/GIP); mid-stage data readout for oral candidate due in 2025 (barrons.com).
• Strong analyst sentiment: Jefferies forecasts ~223% upside
________________________________________
3. Insmed (NASDAQ: INSM)
• Catalyst: Phase III/inhalable powder treprostinil palmitil for pulmonary arterial hypertension; recent results exceeded expectations; full Phase III data due in 2025
________________________________________
4. Kymera Therapeutics
• Catalyst: Phase I for KT 621 (oral STAT6 degrader for dermatitis/asthma); next-stage readouts expected late 2025–early 2026
• Shares rose ~50% on initial results; further trials underway
________________________________________
5. Arcutis Biotherapeutics (NASDAQ: ARQT)
• Catalyst: Technical breakout potential near $17.75; continued quarterly readouts with rising sales (33% last quarter)
• Upcoming investor calls/publication strategies may accelerate momentum.
________________________________________
6. Rhythm Pharmaceuticals (NASDAQ: RYTM)
• Catalyst: With FDA-approved Imcivree for genetic obesity, further label expansion or mid-to-late-stage trial results anticipated in 2025
• Institutional buying trends and revenue growth support upcoming readouts .
________________________________________
7. BeOne Medicines (Ticker: ONC)
• Catalyst: Early human data in solid tumor oncology; multiple upcoming trials in 2025 .
• Q1 2025 marked first profit; strong institutional support
________________________________________
8. Mesoblast Ltd & Capricor Therapeutics
• Catalyst: Stem-cell therapies targeting GvHD, heart failure, Duchenne muscular dystrophy—key FDA decisions expected in H2 2025
• Maxim Group flags pivotal year for approvals and stock catalysts (marketwatch.com).
________________________________________
9. Acelyrin (NASDAQ: SLRN)
• Catalyst: Phase III results for lonigutamab in thyroid eye disease; shareholder vote on Alumis merger around May 2025
• Merger closing and clinical readouts may drive volatility .
________________________________________
10. ADC Therapeutics & Foghorn Therapeutics & Pyxis Oncology
• Catalysts: Multiple preclinical/early clinical updates presented at AACR (April 2025)
o ADC Therapeutics (ADCT): Readouts on 6 ADC programs (Claudin 6, NaPi2b, etc.).
o Foghorn (FHTX): Preclinical updates on EP300, FHD609, FHD909.
o Pyxis Oncology (PYXS): Phase I ADC and Siglec 15 antibody data.
________________________________________
🔎 How to Monitor These Catalysts
• FDA PDUFA dates (Crinetics, Mesoblast/Capricor, Viking)
• Trial readouts/ASC presentations (Kymera, Insmed, ADC Therapeutics, Foghorn, Pyxis)
• M&A/news events (BeOne, Acelyrin merger)
________________________________________
📊 Summary Table
Ticker Company Upcoming Catalyst Timeframe
CRNX Crinetics PDUFA paltusotine NDA Sep 25, 2025
Viking Viking Therapeutics Injectable Phase III, oral Phase II data From mid-2025
INSM Insmed PAH inhalable Phase III readout Mid-to-late 2025
Kymera Kymera Therapeutics Dermatitis/asthma Phase I → Phase II Late 2025 – 2026
ARQT Arcutis Biotherapeutics Continued quarterly updates Throughout 2025
RYTM Rhythm Pharmaceuticals Label expansion/trial updates 2025
ONC BeOne Medicines Solid tumor trial data 2025
Mesoblast/Capricor Stem-cell stocks FDA decisions H2 2025
SLRN Acelyrin EMA/merger vote + Phase III readout May–Q3 2025
ADCT/FHTX/PYXS AACR presenters Academic readouts on multiple programs April 2025
________________________________________
⚠️ A Word of Caution
Small-cap biotech involves high volatility—catalyst events often drive sharp price swings, both up and down. Thorough due diligence is essential.